Our Approach
Unlike typical grant funding, we offer a truly collaborative approach to project development and delivery. Our intention is not just to fund but to add additional collaborative support and advice to enable the best chances of success for the project.
As part of the first funding call for CF AMR which is now closed, we were looking to help create and advance an exciting and diverse pipeline of preclinical phase projects aimed at treating lung infections in people with Cystic Fibrosis.
In 2023, we launched a new programme, the Collaborative Discovery Programme. The first funding call associated with this programme was entitled: New Therapeutics to treat lung infections in CF. The £3 million fund (provided by LifeArc) will support up to 5 early-stage drug discovery projects that seek to develop new therapeutics to treat lung infections in CF.
We provide collaborative support to overcome barriers together.
Access to CF AMR Syndicate resources, helping to accelerate project delivery.
Drug discovery and disease area insight, with expert advice.
Thinking of joining our network?
Become part of a collaborative community working together to accelerate the development of CF antimicrobials and bring new treatments to people with CF. Join the Network today and get notified of future funding opportunities and activities.
Contact CF AMR Syndicate
Have a question you can’t find the answer to or would like further information?
Collaborative Discovery Programme
The CF AMR Syndicate Collaborative Discovery Programme (CDP) is advancing an exciting and diverse pipeline of preclinical phase projects for Cystic Fibrosis (CF) lung infections. Our £3 million programme (provided by LifeArc) is supporting six early-stage drug discovery projects aligned with the unmet needs identified in our Therapeutic Target Product Profiles (TPP) for CF lung infections.
CDP offers a unique collaborative approach to project development and delivery. As well as funding, our awardees benefit from additional collaborative support, increasing the probability of successful outcomes.
Support through the early development phases to generate essential data packages will position these projects to attract onward funding and investment for further development.
